+ Watch DNDN
on My Watchlist
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Talk about playing with fire. Every time Dendreon dips, I wonder if there's another upward run left or if this is the swirl. I've been sucked into as many swirls as anyone, but on CAPS I make my parameters and stick to my guns. The burn is still obscene, the debt is atrocious, but there's 500M in cash as of the end of Q2 which gives the company at least a year to pull rabbits out of their hat. The only question is, will the rabbit pop out at a share price of 6 or 2?
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions